- AP710 Clinical Aesthetic Procedures: Ultrasound-Guided Dermal Fillers (T/651/9202) Assignment Brief 2026
- AP709 Clinical Aesthetic Procedures: PolyL-Lactic Acid (PLLA) Dermal Fillers (Y/651/9203) Assignment Brief 2026
- Unit 13 Project Management (M/650/4829) Assignment Brief 2026
- Unit 27 Identifying Entrepreneurial Opportunities (A/618/5095) Assignment Brief 2026
- Unit 10 Organisational Strategy (J/650/4826) Assignment Brief 2026
- Unit 7 Leading and Managing People (D/650/4823) Assignment Brief 2026
- ATHE Level 3 Unit 5 Market Research (T/650/4820) Assignment Brief 2026
- Unit 2 How Businesses and Organisations Work (H/650/4816) Assignment Brief 2026
- HSC307 Understanding Dementia Care (F/615/3829) Assignment Brief 2026
- HSC306 Understanding Stroke Care (A/615/3828) Assignment Brief 2026
- HSC305 Understanding Diabetes Care (T/615/3827) Assignment Brief 2026
- HSC304 Person-Centred Care (M/615/3826) Assignment Brief 2026
- HSC303 Promoting Health in the Population (K/615/3825) Assignment Brief 2026
- HSC302 Communication for Health and Social Care (D/615/3824) Assignment Brief 2026
- HSC301 An introduction to Health and Social Care (D/615/3823) Assignment Brief 2026
- Operations and Information Management for Project Managers (K/618/0233) Assignment Brief 2026
- Procurement Risk and Contract Management (R/618/0226) Assignment Brief 2026
- Advanced Research Methods (A/618/0236) Assignment Brief 2026
- Advanced Project and Logistics Management (H/618/0229) Assignment Brief 2026
- Planning, Controlling and Leading a Project (F/618/0223) Assignment Brief 2026
AP707 Clinical Aesthetic Procedures: Botulinum Toxin Injections for the Face (Y/651/9196) Assignment Brief 2026
| University | Qualifi Ltd |
| Subject | AP707 Clinical Aesthetic Procedures: Botulinum Toxin Injections for the Face (Y/651/9196) |
Unit AP707 Clinical Aesthetic Procedures: Botulinum Toxin Injections for the Face Assignment Brief
| Qualification | Qualifi Level 7 Diploma in Clinical Aesthetic Practice (610/7007/5)
Qualifi Level 7 Certificate in Clinical Aesthetic Procedures: Botulinum Toxin Injections (610/7010/5) |
| Unit Reference Number | Y/651/9196 |
| Unit Code | AP707 |
| Unit Title | Clinical Aesthetic Procedures: Botulinum Toxin Injections for the Face |
| RQF Level : | 7 |
| Number of Credits | 15 |
| Total Qualification Time (TQT) | 150 hours |
| Guided Learning Hours (GLH) | 75 hours |
Learning Outcomes and Assessment Criteria
| Learning Outcomes. To achieve this unit a learner must be able to: | Assessment Criteria. Assessment of these outcomes demonstrates a learner can: | NOS/KSBs | ||
| LO1 | Adhere to legal, ethical and professional standards for botulinum toxin procedures
|
1.1 | Obtain and discuss the client’s consultation outcomes and prescription for the botulinum toxin type A procedure from the regulated independent prescriber to include:
• legal, regulatory and organisational requirements • client procedure plan and areas to be treated • advice, support and guidance • emergency plan • medicine management policy • pain management strategy |
PC1, PC2
KU1, KU2, KU3 KU18 KU19
|
| 1.2 |
Describe the types, composition and pharmacological effects of chemical compounds in botulinum toxin solutions to include: how religion and belief can prohibit a botulinum toxin type A procedure |
KU6 | ||
| 1.3 | Explain the physiological effect botulinum toxin type A solution has on the targeted and surrounding facial muscle structures to include:
• adaptation of injection techniques • adaptation of depth and placement |
KU7 | ||
| 1.5 | Explain the purpose, use and limitations of botulinum toxin type A procedures in relation to:
• past and current medical history • previous non-surgical cosmetic and/or dental procedure history • relevant lifestyle factors • contraindicated medication and medical conditions • the client’s physical and psychological suitability for the non-surgical cosmetic procedure • client expectations |
KU8
|
||
| 1.6 | Explain t he regulatory and legislative requirements for prescription-only medicines to include licensed and offlabel product use | KU12 | ||
| 1.7 | Explain the licensed indicated use of prescription-only medicines and when and why they can be used off-label considering:
• safety • treatment area • suitability • agreement with the regulated independent prescriber
|
KU13 | ||
| 1.8 | Explain the legislative requirements and restrictions for sourcing, storing and using licensed topical anaesthetics | KU15 | ||
| 1.9 | Describe the health and safety responsibilities in line with legislation before, during and after the botulinum toxin type A procedure | KU16 | ||
| 1.10 | Explain the legislative and indemnity requirements for gaining signed, informed consent for the elective nonsurgical cosmetic procedure
|
KU25 | ||
| 1.11 | Explain the legislative, insurance and organisational requirements for taking and storing visual media of the client’s treatment area | KU30 | ||
| 1.12 | Explain the legislative and regulatory requirements for completing and storing the client’s medical and nonsurgical cosmetic procedure records | KU31 | ||
| LO2 | Conduct a client consultation and develop a personalised procedure plan for botulinum toxin procedures
|
2.1 | Conduct a structured face-to-face client consultation, ensuring compliance with health and safety before, during, and after the botulinum toxin type A procedure, and effectively use visual aids to explain anticipated physical effects | PC3
KU17, KU21, KU32 |
| 2.2 | Discuss client objectives, concerns, expectations and desired outcomes to inform the botulinum toxin type A procedure plan including; fee structure, treatment options, and alternative treatment options | PC4
KU20, KU22 |
||
| 2.3 | Establish the botulinum toxin type A procedure plan in accordance with legislative requirements and organisational policies and procedures | PC5 | ||
| 2.4 | Reiterate, confirm and agree with the client that they have understood the proposed botulinum toxin type A procedure and pain management to including:
• contra-actions • adverse reactions
|
PC6
KU9, KU11 |
||
| 2.5 | Obtain and review the client’s written informed consent for the botulinum toxin type A procedure and pain management, allowing an adequate time scale for the client to make an informed choice digital skin scanner | PC7, PC8
KU14, KU23, KU24 |
||
| 2.6 | Obtain the fulfilled prescription from the pharmacist with the client’s informed consent to include:
• patient-specific direction • saline reconstitution solutions • device and needle type • storage instructions • waste disposal protocol |
PC9 | ||
| LO3 | Deliver botulinum toxin
procedures safely and effectively
|
3.1 |
Select an effective hygiene preparation product to meet the client’s needs in accordance with the manufacturer’s instructions |
PC10,
KU26 |
| 3.2 | Prepare the client’s treatment area in line with botulinum toxin type A protocol and risk management strategies, including marking the procedure sites where applicable | PC11 | ||
| 3.3 | Inject the botulinum toxin type A solution with a sterile, single-use needle following the botulinum toxin type A procedure protocol to include:
• adaptation of injection techniques, depth and placement • in accordance with the preprocedure markings if applicable |
PC12,
KU27 |
||
| 3.4 | Monitor the client’s health, wellbeing and skin response throughout the botulinum toxin type A procedure, ensuring compliance with legislative requirements and organisational policies and procedures | PC13
KU28 |
||
| 3.5 | In the event of an adverse reaction or incident, the aesthetic practitioner must take prompt corrective action following the emergency plan to include:
promptly obtain medical intervention from the designated healthcare professional when complications arise and |
PC14
KU9, KU10, KU29 |
||
| prescription-only medicine is required | ||||
| 3.6 | Conclude the procedure in line with the botulinum toxin type A protocol, legislative requirements and organisational procedures to include:
removing any pre-procedure markings if applicable |
PC15 | ||
| 3.7 | Capture and securely store clientapproved images of the procedure area in compliance with insurance and organisation requirements | PC16 | ||
| 3.8 | Complete the client’s non-surgical cosmetic procedure records and store in line with data legislation | PC17 | ||
| LO4 | Provide aftercare for botulinum toxin procedures and review procedure outcomes
|
4.1 | Provide verbal and written instructions and confirm the client’s receipt of pre and post-procedure advice to include:
• the regulated independent prescriber’s contact details • emergency plan • contingency plan in the event of absence |
PC19
KU36 |
| 4.2 | Discuss the outcomes and agree future procedures with the client | PC21 | ||
| 4.3 | Discuss, evaluate and record the outcomes with the regulated independent prescriber and agree further action and future procedures | PC20
KU34, KU35 |
||
| LO5 | Reflect on practice and engage in continuing professional development
|
5.1 | Keep a reflective journal, review the botulinum toxin procedure and evaluate own strengths and areas for improvement | PC18,
KU33 |
| 5.2 | Explain the importance in engaging in, and documenting continuous professional development including keeping updated on policies, procedures and best practice guidance | KU4 | ||
Need Help With Your AP707 Clinical Aesthetic Procedures (Y/651/9196) Assignment?
Many students find the AP707 Clinical Aesthetic Procedures assignment difficult because it involves legal requirements, client consultation, pharmacology, injection protocols, aftercare, and reflective practice all in one detailed assessment. Some also struggle with professional terminology, treatment planning, and linking theory with safe clinical practice. But now you do not need to worry because Students Assignment Help provides custom-written and plagiarism-free healthcare assignment help based on your exact qualification requirements. You can also explore our assignment samples to better understand reflective journals, procedure planning, and clinical documentation. Order trusted help with assignment today and receive fully human-written academic support delivered before your deadline.


